Immunic, inc. to participate in investor and scientific conferences in february

New york, feb. 8, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in february: february 16-18: svb leerink 11th annual global healthcare conference. daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking